Your Exclusive Invitation to take part in an

• Quality Results• Trusted Reputation• Standard of Excellence

For the complete Intellectual Property Ownership of the

Positive and Negative Syndrome Scale™ (PANSS™)

72.35%PERMISSIONS & LICENSING

27.65%PAPER BASED

67.78%PHARMACEUTICAL

22.70%CONTRACT RESEARCH ORGANIZATION

6.34%HEALTHCARE*

3.18%OTHER**

* Healthcare includes: Biotechnology, HMO, Hospitals, Mental Health Clinics, and Private Practice** Other includes: University, Government, and Distibutor

Quick Reference

Age18 and older

Administration TimePANSS: variesSCI-PANSS: 30-40 minutesIQ-PANSS: varies

FormatHandscoredPermissions Licensing

Number of ItemsPANSS: 33SCI-PANSS: 179IQ-PANSS: 14

Qualification LevelB-level

Additional Resources AvailablePANSS Technical ManualPANSS QuikScore Forms

You are invited to participate in an exclusive auction for The Positive and Negative Syndrome Scale™ (PANSS™) suite of products.

The PANSS represents a gold-standard in assessment of symptom presence and severity in schizophrenia and for the first time it’s available to own along with the SCI-PANSS and the IQ-PANSS accompaniments. No longer will you need permissions/licensing to use it in drug and clinical trials. Better yet, control who you allow to access this in-demand assessment. Act now to secure your rights to this powerful tool.

The Positive and Negative Syndrome Scale (PANSS)™ provides a broad-based, standardized evaluation of psychopathology dimensions that help to characterize the patient’s clinical profile and to monitor changes with treatment. The PANSS is based on findings that schizophrenia comprises at least two distinct symptom domains: the positive symptom consisting of productive symptoms, such as hallucinations and delusions, usually responding well to neuroleptic treatment; and the negative symptoms consisting of deficit features, such as blunted affect and passive social withdrawal, indicative of poor premorbid status, neuroleptic resistance, and poor prognosis.

PANSS Overview

The PANSS is the most researched and widely used assessment of symptom presence and severity in schizophrenia. It is used as an outcome measure in numerous FDA approved clinical trials as well as in private practice and hospital settings (see figure 1.0). After nearly 30 years of use, the PANSS has cultivated a reputation for excellence which, coupled with its exceptional margins, makes it a highly profitable tool (see figure 3.0). Research with the PANSS has found the instrument to be highly reliable and valid, and the positive-negative and other symptom scales to be significantly related to differences along historical, genealogical, psychometric, clinical, psychopharmacological, and prognostic variables.

A Trusted Asset

84.9

9%15

.01%

PRO

FIT

MA

RGIN

PAN

SS P

rofit

abili

ty

PAN

SS D

eliv

ery

Met

hod

PAN

SS C

lient

Mix

Figu

re 1

.0

Figu

re 2

.0

Figu

re 3

.0

COST

OF

GO

OD

S

Auction DetailsExpressions of interest and bids can be submitted between June 30 and July 15, 2016. Auction closes August 19, 2016. Please contact Clinton Agius for further details and/ or to place a bid.

COUNTRIES Where PANSS is Used and/or Translated

The PANSS has been well documented with over 12,000 citations in scientific literature. The assessment has been used in over 1,500 clinical studies by over 200 Pharmaceutical & Clinical Research Organizations in more than 40 countries (see figure 4.0).

Drug Efficacy: The PANSS is used in clinical trials as a primary and secondary outcome measure for drug efficacy.

PTSD: The assessment is used to investigate the link between PTSD symptoms (agitation and psychotic symp-toms) and platelet monoamine oxidase type B (MAOB) polymorphisms.

Remission: Eight items on the assessment are effectively used for determining symptom remission. Acute Agitation: PANSS Excited Component (PANSS-EC) is used to demonstrate the utility of sublingual asenap-ine for acute agitation. It’s also used as an outcome to determine treatment effectiveness of new drugs for agita-tion and hostility in patients with schizophrenia and other psychotic disorders.

Research: Five-factor Pentagonal model of the PANSS has been found to have a biological basis and can be use-ful in illuminating domain specific psychopathology in schizophrenia.

Schizophrenia and beyond: The PANSS is extensively used to evaluate symptomatology in other psychotic disor-ders, including personality disorders, affective psychoses, mania, and substance related psychopathology.

The PANSS in Practice

The PANSS is a 33 item scale yielding separate scores along nine clinical dimensions including the positive and negative symptoms, a composite index, general psychopathology, plus 3 items assessing aggression.

The PANSS’s QuikScore paper-and-pencil format is designed for simple usage and scoring. Permissions/licensing allows for easy deployment on a variety of platforms and accounts for a large portion of the PANSS’s use (see figure 2). The Pentagonal scoring method is another asset of the PANSS. It uses 25 PANSS items organized into five scales which can depict the nature of the patient’s psychopathology along five dimensions. The dimensions include: Negative, Positive, Dysphoric Mood, Activation, and Autistic Preoccupation.

In addition, the accompanying SCI–PANSS, a semi-structured interview, ensures that all content areas are covered within the interview and the IQ-PANSS provides a convenient method for recording information from care workers or family members of the patient.

Using the Assessment

Figure 4.0

Access to the PANSS is often a critical component to ensuring clinical trial business. Don’t miss out on this exciting opportunity to secure your ownership of this assessment.

Your Key to Unlocking Clinical Trial Business

ABOUT THE AUTHORSStanley R. Kay, Ph.D.: In addition to his work on the PANSS, Dr. Kay also developed the Cognitive Diagnostic Battery, published over 100 peer reviewed articles, and cared for hundreds of patients.

Lewis A. Opler, M.D., Ph.D.: Dr. Opler is a Professor of Clinical Psychiatry at Columbia Uni-versity and holds the rank of Adjunct Professor of Psychiatry at the NYU School of Medicine, as well as Chief Medical Officer and Director of the Research Division of the New York State Office of Mental Health. He is the co-author of over 200 scientific publica-tions, two books, and has been included on the prestigious Best Doctors in America list for several years. He is also the Chair of the Expert Consensus Panel for the PANSS Institute.

Abraham Fiszbein, M.D.: Dr. Fiszbein is a Bilingual Adult, Adolescent, and Child Psychiatrist. He studied under the mentorship of Dr. Opler and participated in an intensive Research Fellowship at AECOM/MMC, where he later became an Assistant Professor of Psychiatry. He currently has a private practice in Las Cruces, NM.

OTHER CONTRIBUTORSMark Opler, Ph.D.: Dr. Opler serves as the Chief Scientific Officer (CSO) at ProPhase LLC and is the Executive Director of the PANSS Institute (TPI). He is also an Adjunct Assistant Professor of Psychiatry at New York University and holds the rank of Assistant Professor of Clinical Neuroscience at Columbia University Medical Center.

Paul Michael Ramirez, Ph.D.: Dr. Ramirez is a Professor of Clinical Neuropsychology, Psychopathol-ogy, and Psychopharmacology at Long Island University in New York City where he is also the Chair. He is widely published in psychiatric journals and is the president of CNS Ratings, a rater-training company.

Leonard White, Ph.D.: Dr. White is an assistant Professor of Psychiatry at Mount Sinai School of Medicine and is a senior clinical psychologist at the Clinical Neuroscience Center Pil-grim Psychiatric Center. He is the principal author of the Pentagonal Model for interpretation of the PANSS and has published several papers examining its validity.

If you would like to learn more about securing the Intellectual Property of the PANSS, please email:

Clinton AgiusVice President, Business Development & Marketing MHS Inc.,Clinton.agius@mhs.com